Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

Abrupt high-latitude climate events and decoupled seasonal trends during the Eemian.

Salonen JS, Helmens KF, Brendryen J, Kuosmanen N, Väliranta M, Goring S, Korpela M, Kylander M, Philip A, Plikk A, Renssen H, Luoto M.

Nat Commun. 2018 Jul 20;9(1):2851. doi: 10.1038/s41467-018-05314-1.

PMID:
30030443
2.

The management and survival outcomes of nasopharyngeal cancer in the Nordic countries.

Mäkitie A, Ruuskanen M, Bentzen J, Brun E, Gebre-Medhin M, Friesland S, Marsk E, Hammarstedt-Nordenvall L, Gille E, Reizenstein J, Adell G, Farnebo L, Rzepecki J, Haugen H, Söderström K, Zackrisson B, Bergström S, Lödén B, Cederblad L, Laurell G, Smeland E, Folkvard Evensen J, Lund JÅ, Tøndel H, Karlsdottir Å, Jóhannsson J, Johansen J, Kristensen CA, Jensen K, Andersen LJ, Koivunen P, Korpela M, Voutilainen L, Wigren T, Minn H, Joensuu H, Overgaard J, Saarilahti K.

Acta Oncol. 2018 Apr;57(4):557-560. doi: 10.1080/0284186X.2017.1408961. Epub 2017 Dec 5. No abstract available.

PMID:
29202641
3.

Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial.

Väänänen T, Vuolteenaho K, Kautiainen H, Nieminen R, Möttönen T, Hannonen P, Korpela M, Kauppi MJ, Laiho K, Kaipiainen-Seppänen O, Luosujärvi R, Uusitalo T, Uutela T, Leirisalo-Repo M, Moilanen E; NEO-RACo Study Group.

PLoS One. 2017 Aug 25;12(8):e0183294. doi: 10.1371/journal.pone.0183294. eCollection 2017.

4.

Development spots in communication during the management of the intrapartum period: An interpretive multiple case study in a developing context.

M'Rithaa DKM, Fawcus SR, De la Harpe M, Korpela M.

Afr J Prim Health Care Fam Med. 2017 Jul 31;9(1):e1-e6. doi: 10.4102/phcfm.v9i1.1239.

5.

Outcome of nasopharyngeal carcinoma in Finland: A nationwide study.

Ruuskanen M, Grenman R, Leivo I, Vahlberg T, Mäkitie A, Saarilahti K, Wigren T, Korpela M, Voutilainen L, Koivunen P, Irjala H, Minn H.

Acta Oncol. 2018 Feb;57(2):251-256. doi: 10.1080/0284186X.2017.1346378. Epub 2017 Jul 7.

PMID:
28686479
6.

Reliability of temperature signal in various climate indicators from northern Europe.

Hari P, Aakala T, Hilasvuori E, Häkkinen R, Korhola A, Korpela M, Linkosalo T, Mäkinen H, Nikinmaa E, Nöjd P, Seppä H, Sulkava M, Terhivuo J, Tuomenvirta H, Weckström J, Hollmén J.

PLoS One. 2017 Jun 29;12(6):e0180042. doi: 10.1371/journal.pone.0180042. eCollection 2017.

7.

Newtonian boreal forest ecology: The Scots pine ecosystem as an example.

Hari P, Aakala T, Aalto J, Bäck J, Hollmén J, Jõgiste K, Koupaei KK, Kähkönen MA, Korpela M, Kulmala L, Nikinmaa E, Pumpanen J, Salkinoja-Salonen M, Schiestl-Aalto P, Simojoki A, Havimo M.

PLoS One. 2017 Jun 14;12(6):e0177927. doi: 10.1371/journal.pone.0177927. eCollection 2017.

8.

RAPID3 correlates with ESSPRI and other patient-reported outcomes in patients with primary Sjögren's syndrome.

Pertovaara M, Korpela M.

Clin Exp Rheumatol. 2017 Jul-Aug;35(4):718. Epub 2017 May 15. No abstract available.

PMID:
28516885
9.

Anti-carbonic anhydrase autoantibodies and serum beta-2 microglobulin correlate with the ClinESSDAI score in patients with Sjögren's syndrome.

Pertovaara M, Parkkila S, Korpela M.

Clin Exp Rheumatol. 2017 Mar-Apr;35(2):351. Epub 2017 Jan 5. No abstract available.

PMID:
28079504
10.

Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials.

Levitsky A, Wick MC, Möttönen T, Leirisalo-Repo M, Laasonen L, Korpela M, van Vollenhoven RF, Rantalaiho V.

Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1065-1071. Epub 2016 Aug 31.

PMID:
27607411
11.

Intra-articular glucocorticoid injections should not be neglected in the remission targeted treatment of early rheumatoid arthritis: a post hoc analysis from the NEO-RACo trial.

Kuusalo LA, Puolakka KT, Kautiainen H, Alasaarela EM, Hannonen PJ, Julkunen HA, Kaipiainen-Seppänen OA, Korpela MM, Möttönen TT, Paimela LH, Peltomaa RL, Yli-Kerttula TK, Leirisalo-Repo M, Rantalaiho VM; NEO-RACo Study Group.

Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1038-1044. Epub 2016 Aug 2.

PMID:
27494516
12.

Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.

Joensuu JT, Aaltonen KJ, Aronen P, Sokka T, Puolakka K, Tuompo R, Korpela M, Vasala M, Ilva K, Nordström D, Blom M.

Rheumatology (Oxford). 2016 Oct;55(10):1803-11. doi: 10.1093/rheumatology/kew264. Epub 2016 Jun 27.

PMID:
27354689
13.

Regular physical activity is associated with lower levels of ESSPRI and other favourable patient-reported outcomes in patients with primary Sjögren's syndrome.

Pertovaara M, Korpela M.

Clin Exp Rheumatol. 2016 May-Jun;34(3):560. Epub 2016 Mar 11. No abstract available.

PMID:
26967922
14.

The expected and actual communication of health care workers during the management of intrapartum: An interpretive multiple case study.

M'Rithaa DK, Fawcus S, Korpela M, De la Harpe R.

Afr J Prim Health Care Fam Med. 2015 Dec 3;7(1):911. doi: 10.4102/phcfm.v7i1.911.

15.

Cost-Effectiveness of Biologics Compared to Conventional Disease-Modifying Antirheumatic Drugs for Treatment of Rheumatoid Arthritis in Finland.

Joensuu JT, Aaltonen KJ, Aronen P, Sokka T, Puolakka K, Tuompo R, Korpela M, Vasala M, Ilva K, Nordström D, Blom M.

Value Health. 2015 Nov;18(7):A648. doi: 10.1016/j.jval.2015.09.2328. Epub 2015 Oct 20. No abstract available.

16.

Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial.

Kuusalo L, Puolakka K, Kautiainen H, Blåfield H, Eklund KK, Ilva K, Kaipiainen-Seppänen O, Karjalainen A, Korpela M, Valleala H, Leirisalo-Repo M, Rantalaiho V; Neo-RACo Study Group.

Scand J Rheumatol. 2015;44(6):449-55. doi: 10.3109/03009742.2015.1043142. Epub 2015 Aug 31.

PMID:
26324784
17.

Electrostatic Architecture of the Infectious Salmon Anemia Virus (ISAV) Core Fusion Protein Illustrates a Carboxyl-Carboxylate pH Sensor.

Cook JD, Soto-Montoya H, Korpela MK, Lee JE.

J Biol Chem. 2015 Jul 24;290(30):18495-504. doi: 10.1074/jbc.M115.644781. Epub 2015 Jun 16.

18.

Epstein-Barr virus in peripheral blood is associated with response to rituximab therapy in rheumatoid arthritis patients.

Valleala H, Kauppi MJ, Kouri VP, Korpela M.

Clin Rheumatol. 2015 Aug;34(8):1485-8. doi: 10.1007/s10067-015-2992-0. Epub 2015 Jun 16.

PMID:
26076687
19.

[Childhood and adolescent cancer was cured--how to support health in adulthood?].

Taskinen M, Vettenranta K, Jokinen E, Lehtinen T, Arola M, Korpela M, Möttönen M, Pesola J, Voutilainen L, Vähäkylä-Aulo A, Mäkinen S, Suontausta-Kyläinpää S, Jyrkkiö S, Lähteenmäki P.

Duodecim. 2014;130(22-23):2320-30. Review. Finnish.

PMID:
25558594
20.

Long-term real-life experience with rituximab in adult Finnish patients with rheumatoid arthritis refractory or with contraindication to anti-tumor necrosis factor drugs.

Valleala H, Korpela M, Hienonen-Kempas T, Immonen K, Lähteenmäki J, Uusitalo T, Komulainen R, Möttönen T, Hannonen P.

J Clin Rheumatol. 2015 Jan;21(1):24-30. doi: 10.1097/RHU.0000000000000166.

PMID:
25539430
21.

The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels.

Isomäki P, Junttila I, Vidqvist KL, Korpela M, Silvennoinen O.

Rheumatology (Oxford). 2015 Jun;54(6):1103-13. doi: 10.1093/rheumatology/keu430. Epub 2014 Nov 17.

PMID:
25406356
22.

Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomized clinical NEO-RACo trial.

Rantalaiho V, Kautiainen H, Järvenpää S, Korpela M, Malmi T, Hannonen P, Kaipiainen-Seppänen O, Yli-Kerttula T, Möttönen T, Mustila A, Karjalainen A, Paimela L, Uutela T, Leirisalo-Repo M; NEO-RACo Study Group.

J Rheumatol. 2014 Dec;41(12):2379-85. doi: 10.3899/jrheum.140267. Epub 2014 Oct 1.

PMID:
25274892
23.

Joint symptoms after a faecal culture positive Campylobacter infection associated with a waterborne gastroenteritis outbreak: a questionnaire study.

Uotila T, Korpela M, Vuento R, Laine J, Lumio J, Kuusi M, Virtanen MJ, Mustonen J, Antonen J; Pirkanmaa Waterborne Outbreak Study Group.

Scand J Rheumatol. 2014;43(6):524-6. doi: 10.3109/03009742.2014.920916. Epub 2014 Sep 10. No abstract available.

PMID:
25205145
24.

A nationwide cross-sectional overview of patients with rheumatoid arthritis followed in outpatient specialty clinics in Finland.

Aaltonen KJ, Sokka T, Möttönen T, Korpela M, Komulainen R, Uusitalo T, Salomaa S, Uutela T, Valleala H, Rami Study Group.

Scand J Rheumatol. 2014;43(4):286-90. doi: 10.3109/03009742.2013.876512. Epub 2014 Mar 24.

PMID:
24654994
25.

The duration of gastrointestinal and joint symptoms after a large waterborne outbreak of gastroenteritis in Finland in 2007--a questionnaire-based 15-month follow-up study.

Laine J, Lumio J, Toikkanen S, Virtanen MJ, Uotila T, Korpela M, Kujansuu E, Kuusi M.

PLoS One. 2014 Jan 17;9(1):e85457. doi: 10.1371/journal.pone.0085457. eCollection 2014.

26.

ESSPRI and other patient-reported indices in patients with primary Sjogren's syndrome during 100 consecutive outpatient visits at one rheumatological clinic.

Pertovaara M, Korpela M.

Rheumatology (Oxford). 2014 May;53(5):927-31. doi: 10.1093/rheumatology/ket476. Epub 2014 Jan 24.

PMID:
24464708
27.

User participation in healthcare IT development: a developers' viewpoint in Finland.

Martikainen S, Korpela M, Tiihonen T.

Int J Med Inform. 2014 Mar;83(3):189-200. doi: 10.1016/j.ijmedinf.2013.12.003. Epub 2013 Dec 16.

PMID:
24382475
28.

Physicians' adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis: a subanalysis of the FIN-RACo trial.

Rantalaiho V, Kautiainen H, Korpela M, Puolakka K, Blåfield H, Ilva K, Hannonen P, Leirisalo-Repo M, Möttönen T; FIN-RACo Study Group.

Ann Rheum Dis. 2014 Apr;73(4):788-90. doi: 10.1136/annrheumdis-2013-204271. Epub 2013 Dec 2. No abstract available.

PMID:
24297374
29.
30.

How to co-develop services, work, and information systems in healthcare: the daisy approach.

Korpela M, Ikävalko P, Luukkonen I, Martikainen S, Palmén M, Tiihonen T, Toivanen M, Vainikainen V.

Stud Health Technol Inform. 2013;194:126-32.

PMID:
23941943
31.
32.

Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.

Rantalaiho V, Kautiainen H, Korpela M, Hannonen P, Kaipiainen-Seppänen O, Möttönen T, Kauppi M, Karjalainen A, Laiho K, Laasonen L, Hakola M, Peltomaa R, Leirisalo-Repo M; NEO-RACo Study Group.

Ann Rheum Dis. 2014 Nov;73(11):1954-61. doi: 10.1136/annrheumdis-2013-203497. Epub 2013 Aug 1.

PMID:
23908187
33.

Disease activity of idiopathic juvenile arthritis continues through adolescence despite the use of biologic therapies.

Vidqvist KL, Malin M, Varjolahti-Lehtinen T, Korpela MM.

Rheumatology (Oxford). 2013 Nov;52(11):1999-2003. doi: 10.1093/rheumatology/ket256. Epub 2013 Jul 27.

PMID:
23893666
34.

Outcome of reactive arthritis after an extensive Finnish waterborne gastroenteritis outbreak: a 1-year prospective follow-up study.

Uotila TM, Antonen JA, Paakkala AS, Mustonen JT, Korpela MM; Pirkanmaa Waterborne Outbreak Study Group.

Clin Rheumatol. 2013 Aug;32(8):1139-45. doi: 10.1007/s10067-013-2247-x. Epub 2013 Apr 5.

PMID:
23559390
35.

Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial.

Rantalaiho VM, Kautiainen H, Korpela M, Hannonen PJ, Leirisalo-Repo M, Möttönen T; FIN-RACo Trial Group.

Ann Rheum Dis. 2013 May;72(5):786-8. doi: 10.1136/annrheumdis-2012-202737. Epub 2013 Jan 24. No abstract available.

PMID:
23349132
36.

Do the 2010 ACR/EULAR or ACR 1987 classification criteria predict erosive disease in early arthritis?

Mäkinen H, Kaarela K, Huhtala H, Hannonen PJ, Korpela M, Sokka T.

Ann Rheum Dis. 2013 May;72(5):745-7. doi: 10.1136/annrheumdis-2012-201943. Epub 2012 Nov 21.

PMID:
23172747
37.

Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-α therapy resistant reactive amyloidosis.

Hakala M, Immonen K, Korpela M, Vasala M, Kauppi MJ.

Ann Rheum Dis. 2013 Mar;72(3):464-5. doi: 10.1136/annrheumdis-2012-202156. Epub 2012 Nov 12. No abstract available.

PMID:
23148310
38.

Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis.

Rantalaiho V, Puolakka K, Korpela M, Hannonen P, Möttönen T.

Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S27-31. Epub 2012 Oct 16.

PMID:
23073350
39.

Sustained response to rituximab in a patient with Sjögren´s syndrome and severe refractory polyneuropathy.

Pertovaara M, Korpela M.

Clin Exp Rheumatol. 2012 Sep-Oct;30(5):808; author reply 809. Epub 2012 Oct 17. No abstract available.

PMID:
22992382
40.

Efficacy of stabilisation splint treatment on temporomandibular disorders.

Niemelä K, Korpela M, Raustia A, Ylöstalo P, Sipilä K.

J Oral Rehabil. 2012 Nov;39(11):799-804. doi: 10.1111/j.1365-2842.2012.02335.x. Epub 2012 Jul 19.

PMID:
22809314
41.

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).

Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipiainen-Seppänen O, Luosujärvi R, Luukkainen R, Karjalainen A, Blåfield H, Uutela T, Ilva K, Julkunen HA, Paimela L, Puolakka K, Moilanen E, Hannonen PJ, Möttönen T; NEO-RACo Study Group.

Ann Rheum Dis. 2013 Jun;72(6):851-7. doi: 10.1136/annrheumdis-2012-201365. Epub 2012 Jun 30.

PMID:
22753402
42.

Decline in work disability caused by early rheumatoid arthritis: results from a nationwide Finnish register, 2000-8.

Rantalaiho VM, Kautiainen H, Järvenpää S, Virta L, Pohjolainen T, Korpela M, Möttönen T, Puolakka K.

Ann Rheum Dis. 2013 May;72(5):672-7. doi: 10.1136/annrheumdis-2011-200701. Epub 2012 Jun 7.

PMID:
22679306
43.

Mitochondrial recessive ataxia syndrome mimicking dominant spinocerebellar ataxia.

Palin EJ, Hakonen AH, Korpela M, Paetau A, Suomalainen A.

J Neurol Sci. 2012 Apr 15;315(1-2):160-3. doi: 10.1016/j.jns.2011.11.028. Epub 2011 Dec 12.

PMID:
22166854
44.

Joint symptoms after a large waterborne gastroenteritis outbreak--a controlled, population-based questionnaire study.

Laine J, Uotila T, Antonen J, Korpela M, Kujansuu E, Lumio J, Huovinen E, Mustonen J, Ruutu P, Virtanen MJ, Kuusi M; Pirkanmaa Waterborne Outbreak Study Group.

Rheumatology (Oxford). 2012 Mar;51(3):513-8. doi: 10.1093/rheumatology/ker320. Epub 2011 Nov 24.

PMID:
22120464
45.

Physicians' experiences of participation in healthcare IT development in Finland: willing but not able.

Martikainen S, Viitanen J, Korpela M, Lääveri T.

Int J Med Inform. 2012 Feb;81(2):98-113. doi: 10.1016/j.ijmedinf.2011.08.014. Epub 2011 Sep 28.

PMID:
21956004
46.

Thymidine kinase 2 mutations in autosomal recessive progressive external ophthalmoplegia with multiple mitochondrial DNA deletions.

Tyynismaa H, Sun R, Ahola-Erkkilä S, Almusa H, Pöyhönen R, Korpela M, Honkaniemi J, Isohanni P, Paetau A, Wang L, Suomalainen A.

Hum Mol Genet. 2012 Jan 1;21(1):66-75. doi: 10.1093/hmg/ddr438. Epub 2011 Sep 21.

PMID:
21937588
47.

Assessing the role of a site visit in adopting activity driven methods.

Luukkonen I, Saranto K, Korpela M.

Stud Health Technol Inform. 2011;169:422-6.

PMID:
21893785
48.

FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study.

Suomalainen A, Elo JM, Pietiläinen KH, Hakonen AH, Sevastianova K, Korpela M, Isohanni P, Marjavaara SK, Tyni T, Kiuru-Enari S, Pihko H, Darin N, Õunap K, Kluijtmans LA, Paetau A, Buzkova J, Bindoff LA, Annunen-Rasila J, Uusimaa J, Rissanen A, Yki-Järvinen H, Hirano M, Tulinius M, Smeitink J, Tyynismaa H.

Lancet Neurol. 2011 Sep;10(9):806-18. doi: 10.1016/S1474-4422(11)70155-7. Epub 2011 Aug 3.

PMID:
21820356
49.

Estimated collective effective dose to the population from X-ray and nuclear medicine examinations in Finland.

Bly R, Järvinen H, Korpela MH, Tenkanen-Rautakoski P, Mäkinen A.

Radiat Prot Dosimetry. 2011 Sep;147(1-2):233-6. doi: 10.1093/rpd/ncr334. Epub 2011 Aug 3.

PMID:
21816721
50.

Reactive arthritis in a population exposed to an extensive waterborne gastroenteritis outbreak after sewage contamination in Pirkanmaa, Finland.

Uotila T, Antonen J, Laine J, Kujansuu E, Haapala AM, Lumio J, Vuento R, Oksa H, Herrala J, Kuusi M, Mustonen J, Korpela M; Pirkanmaa Waterborne Outbreak Study Group.

Scand J Rheumatol. 2011;40(5):358-62. doi: 10.3109/03009742.2011.562533. Epub 2011 Jun 17.

PMID:
21679096

Supplemental Content

Loading ...
Support Center